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Abstract Nicotinic acetylcholine receptors (nAChRs) are
membrane ligand-gated cation channels whose activation is
triggered by the binding of the endogenous neurotransmitter
acetylcholine or other biologic compounds including nicotine.
Their roles in synaptic transmission in the central and periph-
eral nervous system as well as in the neuromuscular junction
have been extensively studied. Recent implications of nAChRs
in intracellular signaling and their detection in peripheral
nonneural cells (including epithelial cells and immune cells)
have renewed the interest for this class of ionotropic receptors.
In the present review, we focus our attention on the potential use
of nicotinic cholinergic signaling in the treatment of metabolic
diseases (such as obesity and diabetes) in browsing functions of
nAChRs in adipose tissue and pancreatic islet biology. In fact,
different nAChR subunits can be detected in these metabolic
tissues, as well as in immune cells interacting with them.
Various rodent models of obesity and diabetes benefit from
stimulation of the nicotinic cholinergic pathway, whereas mice
deficient for some nAChRs, in particular the a7 nAChR sub-
unit, harbor a worsened metabolic phenotype. In contrast to
potential therapeutic applications in metabolic diseases, an
overstimulation of this signaling pathway during the early stage
of development (typically through nicotine exposure during
fetal life) presents deleterious consequences on ontogeny and
functionality of adipose tissue and the endocrine pancreas
which persist throughout life.
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Abbreviations
ACh Acetylcholine
AChE Acetylcholinesterase
AKT Protein kinase B
AMPK AMP-activated protein kinase
BAT Brown adipose tissue
ChAT Choline acetyltransferase
CREB cAMP response element-binding protein
DIO Diet-induced obesity
DOHaD Developmental Origins of Health and
Disease
FFA Free fatty acid
F-FDG Fluorodeoxyglucose
GDP Guanosine-50-diphosphate
IL Interleukin
JAK2/STAT3 Janus kinase 2 and signal transducer and
activator of transcription 3
MCP-1 Monocyte chemoattractant protein-1
nAChR Nicotinic acetylcholine receptor
NPY Neuropeptide Y
PI3-kinase Phosphatidylinositide 3-kinase
POMC Proopiomelanocortin
PPAR-c Peroxisome proliferator-activated receptor
gamma
SNP Single nucleotide polymorphism
T1D Type 1 diabetes
TNF-a Tumor necrosis factor alpha
UCP-1 Uncoupling protein 1
WAT White adipose tissue
Sum-up of Nicotinic Cholinergic Signaling Biology
Acetylcholine (ACh) is a small organic molecule initially
discovered by H.H. Dale and later identified by O. Loewi
as the first neurotransmitter. Dale and Loewi jointly
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received in 1936 the Nobel Prize in physiology or medicine
for their discoveries ‘‘relating to chemical transmission of
nerve impulses’’ (Raju 1999). ACh is synthesized intra-
cellularly by the enzyme choline acetyltransferase (ChAT)
from choline and acetyl-coenzyme A before being released
into the extracellular space to act on synaptic-adjacent
cells. In contrast, the enzyme acetylcholinesterase (AChE)
can rapidly clear the extracellular ACh pool into its inac-
tive metabolites choline and acetate. This signaling system
is targeted by various biological modulators which can, for
example, inhibit ACh release or AChE activity. Sensitivity
to natural ACh mimetics has allowed deciphering between
two different cholinergic signaling pathways. Muscarine, a
poisonous molecule found in mushrooms, induces a strong
activation of the peripheral parasympathetic nervous sys-
tem (muscarinic syndrome) that can end in convulsions and
death. Nicotine, a natural alkaloid produced by the tobacco
plant, is one of the most widely consumed psychostimu-
lants, inducing strong behavioral dependence. These two
molecules act via distinct types of cholinergic receptors.
The muscarinic ACh receptors (AChRs M1–5) consist of a
family of five metabotropic or second messenger-coupled
receptors (Eglen 2012; Ishii and Kurachi 2006). On the
other hand, the nicotinic AChRs (nAChRs) consist of a
family of ligand-gated cation channels (Albuquerque et al.
2009; Changeux 2012). Purification of protein extracts and
electronic microscopy have revealed amino acid sequence
and size of nAChR (Changeux et al. 1970; Changeux 1990)
before later cloning revealed the chromosomal location of a
total of 16 genes coding for different nAChR subunits in
mammalian genomes: 9 a subunits (CHRNA 1–7, CHRNA
9–10), 4 b subunits (CHRNB 1–4) and 3 atypical c, d, e
subunits (CHRNG, CHRND, CHRNE) (Albuquerque et al.
2009). These genes are probably from a common ancestor
through a duplication and mutation process, since they are
highly conserved throughout evolution (Le Novere and
Changeux 1995). The pentameric structure initially
described (Hucho and Changeux 1973) and confirmed by
refined modeling at 4A resolution (Unwin 2005) consists of
a symmetrical arrangement of the five subunits around a
central pore. Each subunit possesses four transmembrane
domains with their N- and C-terminus located extracellu-
larly. nAChRs can be classically subclassed as muscular or
neuronal. The muscular nAChR is a heteropentameric
protein composed of (a1)2, b1, d, c subunits in the fetus
and (a1)2, b1, d, e subunits in the adult. The neuronal
nAChRs can be heteropentamerics, resulting from the
assembly of different subunits with at least one of them
being a, or homopentameric when composed of five
identical a subunits (typically the a7 nAChR). The subunit
composition of nAChRs determines their expression pat-
tern, function and pharmacologic properties (such as
agonist sensitivity or desensitizing period) (Hogg et al.
2003; Hurst et al. 2013; Lindstrom 1996). Functionally,
non-muscular nAChRs are generally categorized as high-
affinity nicotine binding receptors (integrating a4 sub-
units), a-bungarotoxin-sensitive neuronal nAChRs
(composed of an a7 subunit) and ganglionic receptors
(composed of a3 and b4 subunits) (Hogg et al. 2003; Hurst
et al. 2013; Lindstrom 1996). Mechanistically, a7 nAChRs
are opened by relatively low nicotine concentrations, but
then rapidly desensitized contrary to a3/b4 nAChR
receptors, insensitive to low nicotine concentrations and
slow to desensitize (Hogg et al. 2003; Hurst et al. 2013;
Lindstrom 1996). Ionic selectivity also differentiates
nAChRs, since a7 nAChR specifically presents high per-
meability to Ca2? exceeding that of other nAChRs (Hogg
et al. 2003; Lindstrom 1996; Uteshev 2012). These features
and advances in understanding the structural/functional
properties of a7 nAChRs through new techniques have
recently suggested its use as a new pharmacotherapeutic
target (Palma et al. 2012; Taly and Charon 2012).
Beyond their channeling activity, nAChRs can be
involved in other intracellular events involving signaling
through PI3-kinase (Huang et al. 2012; Kihara et al. 2001),
ERK1/2 (Dajas-Bailador et al. 2002), AKT (Nakayama
et al. 2002; West et al. 2003) and CREB (Brunzell et al.
2003) pathways. Other regulatory roles for nAChRs have
also been described in proteolysis (Meyer et al. 2002;
Minana et al. 1998) and mitochondrial permeability (Ger-
galova et al. 2012). In addition to their classic roles of
neurotransmitter in the central nervous system, neuro-
muscular junction and autonomic nervous fibers, several
studies have detected nAChR expression in many different
non-neuronal cell types throughout the body (for review
see Conti-Fine et al. 2000; Gahring and Rogers 2005;
Sharma and Vijayaraghavan 2002). These observations
have led to reconsidering the role of ACh not only as a
neurotransmitter, but also as a paracrine messenger able to
interact with peripheral nAChRs. In this context, the
interaction between ACh released by the vagus nerve and
a7 nAChR expressed on macrophages/immune cells
(Wang et al. 2003) represents a ‘‘cholinergic anti-inflam-
matory pathway’’ (Tracey 2007) of particular clinical
interest. There is increasing evidence that smokers have a
lower incidence of certain bowel inflammations (Lakhan
and Kirchgessner 2011) and that use of the cholinergic
anti-inflammatory pathway can present valuable therapeu-
tic perspectives in a wide range of pathologies including
sepsis, endotoxemia, ischemia/reperfusion injury, hemor-
rhagic shock, rheumatoid arthritis and other conditions of
excessive cytokine release (Oke and Tracey 2009; Tracey
2007).
The present review aims to evaluate the function and the
potential therapeutic perspectives of peripheral cholinergic
signaling through nAChRs with special focus on adipose
88 Arch. Immunol. Ther. Exp. (2014) 62:87–101
123
and pancreatic islet biology, two tissues involved in met-
abolic diseases. To this purpose, we then summarize and
discuss: (1) peripheral detection of different subunits
composing nAChRs, (2) experimental results from animal/
cell models exposed to nAChR agonists/antagonists and (3)
basal or challenged phenotypes of animals deficient in
some nAChR subunits, in the context of adipose tissue and
pancreatic islet physiology and their commonly associated
pathologies: obesity and diabetes.
Nicotinic Cholinergic Signaling in Brown and White
Adipose Tissue Biology and Therapeutic Perspectives
in the Treatment of Obesity
White adipose tissue (WAT) functions as a reservoir of
energy stored as triglycerides after a meal and released into
the bloodstream as fatty acids and glycerol between meals.
WAT also acts as a thermal insulator and possesses
endocrine functions, secreting many adipokines (cytokines
produced by adipose tissue) involved in the regulation of
body weight homeostasis and insulin sensitivity (Harwood
2012).
Brown adipose tissue (BAT) is especially abundant in
newborns and in hibernating mammals, but recent studies
have revealed its persistence in human adults (Cypess et al.
2009; van Marken Lichtenbelt et al. 2009). BAT, which is
more innervated and vascularized than WAT, is the main
site of adaptative thermogenesis, a process of heat pro-
duction independent of muscular shivering (Lowell and
Spiegelman 2000).
White and brown adipocytes present morphologic and
molecular features corresponding to their distinct func-
tional roles. In white adipocytes, triglyceride storage is
unilocular (a single lipid droplet is present in the cytosol)
and mitochondria are small and elongated, with randomly
oriented cristae. In contrast, in brown adipocytes, triglyc-
eride storage is multilocular (numerous intracellular small
lipid droplets) and mitochondria are large, numerous,
endowed with laminar cristae and specifically express the
uncoupling protein 1 (UCP-1) responsible for uncoupling
of the oxidative phosphorylation that in turn is responsible
for heat production (Cinti 2005, 2012; Frontini and Cinti
2010).
Peripheral nicotinic cholinergic signaling could be
involved in adipose tissue biology through localization of
nAChRs at various levels, such as in autonomic ganglia,
macrophages, or directly in adipocytes. Studies on knock-
out mice have demonstrated that combinations of a3 with
b2 or b4 subunits compose most nAChRs in autonomic
ganglia of the sympathetic nervous system (Wang et al.
2002) which control adipose tissue activity. Macrophages,
mediating the cholinergic anti-inflammatory pathway
through the a7 nAChR (Wang et al. 2003), are responsible
for the inflammatory response in WAT during obesity
(Weisberg et al. 2003; Xu et al. 2003) and also secrete local
catecholamines during adaptative thermogenesis in BAT
(Nguyen et al. 2011). Adipose tissue possesses functional
cholinergic signaling machinery as shown by its regulated
expression of butyrylcholinesterase (Wang et al. 2011).
Moreover, various nAChR subunits can be detected in
isolated adipocytes (Liu et al. 2004), as well as in BAT and
WAT from rodents (Gochberg-Sarver et al. 2012) and
humans (Cancello et al. 2012).
Nicotine Exposure Effects
In Humans
Epidemiological studies dealing with the metabolic action
of tobacco consumption represent an extensive source of
information, nevertheless difficult to interpret in the con-
text of nicotinic cholinergic action on the adipose
metabolism due to both the simultaneous central and
peripheral action of nicotine and the large panel of bioac-
tive compounds accompanying nicotine in tobacco
(Borgerding and Klus 2005). Selective and focal nicotine
exposure through microdialysis is an interesting technique
used to directly study in vivo nicotinic cholinergic signal-
ing on the human adipose metabolism. In healthy subjects,
this route of nicotine administration causes a concentra-
tion-dependent and reversible increase in the levels of
glycerol release, whereas the opposite effect is induced by
carbachol, demonstrating a dual effect of the nicotinic/
muscarinic cholinergic system on lipolysis (Andersson and
Arner 1995). In healthy male smokers, acute nicotine
infusion increases free fatty acid (FFA) release in adipose
tissue consecutively to an oral glucose tolerance test
(Eliasson et al. 1997). This technique also shows that
nicotine-induced increase in venous, arterial and adipose
glycerol occurs with no change in blood flow (Andersson
and Arner 2001), suggesting an induction of lipolysis
through activation of the classical adrenergic mechanism
and by activation of a nicotinic cholinergic lipolytic
receptor located in the adipose tissue (Andersson and Arner
2001).
In Control Animals
In basal physiologic conditions, changes in body fat pro-
portion parallels changes in body weight in response to
nicotine exposure in rats, suggesting that nicotine admin-
istration decreases body weight by lowering fat stores in
the body (Winders and Grunberg 1990). Central anorexi-
genic features of nicotine (for review see Jo et al. 2002; Li
et al. 2000b; Zoli and Picciotto 2012) can in part explain
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dampening of adipose storage. In fact, numerous hypo-
thalamic neuropeptides involved in the control of food
intake are regulated by nicotinic cholinergic signaling.
Nicotine increases neuropeptide Y (NPY) in different
hypothalamic areas (Jang et al. 2003; Li et al. 2000a), but
limits elevation of NPY during food restriction (Jang et al.
2003). Ex vivo, nicotine directly induces depolarization of
NPY neurons and reduces their glutamatergic input (Huang
et al. 2011). Nicotine also increases expression of orexin
and its receptor in the hypothalamus (Kane et al. 2000), but
decreases orexin binding (Kane et al. 2001) and induces fos
expression in some orexin neuron subpopulations (Pasu-
marthi et al. 2006), linked with the release of glutamate and
ACh in the lateral hypothalamus (Pasumarthi and Fadel
2010). Nicotine also induces release of hypothalamic
monoamines (Fu et al. 2001; Meguid et al. 2000; Sharp and
Matta 1993; Yang et al. 1999), indirect inhibition of mel-
anin-concentrating hormone neurons (through activation of
GABAergic transmission) (Jo et al. 2005), direct stimula-
tion of proopiomelanocortin (POMC) neurons (Huang et al.
2011; Mineur et al. 2011) and inactivation of hypothalamic
AMP-activated protein kinase (AMPK) (Martinez de
Morentin et al. 2012). Different nAChRs seem to mediate
nicotine inhibition of food intake. In the lateral hypothal-
amus, neuronal webs receive cholinergic afferents and
express a4/b2 and a7 nAChRs (Jo et al. 2002; Seguela
et al. 1993; Wada et al. 1989). a3/b4 nAChRs seem rather
implicated in both nicotinic cholinergic stimulation of
POMC neurons (Mineur et al. 2011) and inactivation of
hypothalamic AMPK (Martinez de Morentin et al. 2012).
Interestingly, despite that leptin receptor isoform b and a7
nAChRs share the same JAK2/STAT3 downstream effec-
tors (de Jonge et al. 2005; Hakansson and Meister 1998;
Kloek et al. 2002; Vaisse et al. 1996), and despite the
known effects of nicotine on feeding behavior, the rela-
tionship between a7 nAChRs and leptin sensitivity remains
unexplored. The JAK2/STAT3 activation by a7 nAChR
stimulation (by nicotine or more specific agonists) in situ-
ations of leptin resistance, as seen in obesity, may represent
a new approach to control feeding behavior.
Beyond these central effects indirectly impacting adi-
pose tissue through limitation of energy intake, nicotine
also directly impacts WAT and BAT metabolism. Nicotine
does not seem to alter the composition of the major fatty
acids in adipose triglycerides (Brindis et al. 1973), but
induces a fall in the respiratory quotient (Bishop et al.
2004; Martinez de Morentin et al. 2012) reflecting a rise in
lipid use. Nicotine induces a fall in circulating triglyceride
levels associated with decreased adipose tissue lipoprotein
lipase activity (Chajek-Shaul et al. 1987; Sztalryd et al.
1996). By increasing basal lipolysis, but blunting the
lipolytic response to sympathomimetic b-receptor stimu-
lant isoproterenol, nicotine appears to divert fat storage
from adipose tissue toward utilization by the muscle
(Sztalryd et al. 1996). Nicotine administration also inter-
feres with the endocrine function of adipose tissue by
decreasing circulating leptin levels (Arai et al. 2001) and
gene expression in the perirenal and epididymal WAT (Li
and Kane 2003). Nicotine-induced weight loss is associated
with increased BAT thermogenesis and increased energy
expenditure (Martinez de Morentin et al. 2012). Acute and
chronic exposure to nicotine increases both the turnover of
norepinephrine and the binding of the guanosine-50-
diphosphate (GDP) to BAT mitochondria (Lupien and Bray
1988). Decreased vacuolation, elevated UCP-1 and nor-
epinephrine contents are also observed in BAT in a depot-
specific manner following nicotine administration (Arai
et al. 2001; Brees et al. 2008). Nicotine induces uptake of
18F-FDG in BAT (blockable by a prior injection of b-
adrenergic antagonists) (Baba et al. 2007) and a reversible
noradrenaline release from BAT (blockable by antagonism
of corticotrophin-releasing factor receptor type 1) (Mano-
Otagiri et al. 2009).
In Obesity Models
Lipolytic and thermogenic features of nicotinic cholinergic
signaling previously described in the basal state led to
evaluate its potential weight loss promoting action in dif-
ferent rodent models of obesity. Genetically obese ob/ob
mice subcutaneously injected with nicotine present a rise in
plasma FFA with no change in basal body temperature or
cold-induced hypothermia (Batt and Topping 1979). In
monosodium-L-glutamate obese mice, nicotine treatment
attenuates obesity in the absence of food intake modifica-
tion by significantly increasing norepinephrine turnover,
GDP binding/oxygen consumption in BAT and the resting
metabolic rate (Yoshida et al. 1990). Obese yellow KK
mice chronically treated with nicotine present decreased
weight, smaller subcutaneous and retroperitoneal WAT
depot harboring multilocular cells and ectopic UCP-1 gene
expression leading to the mitigation of obesity (Yoshida
et al. 1999). In Zucker fatty rats, the tumor necrosis factor
(TNF)-a level is specifically lowered in visceral fat pads
(Liu et al. 2001) in response to nicotine administration. In
genetically obese mice with a defective leptin receptor (db/
db) as well as in diet-induced obese (DIO) mice, nicotine
does not change body weight or appetite, but reduces the
inflammation of adipose tissue depots through activation of
the cholinergic anti-inflammatory pathway (Wang et al.
2011). In DIO mice, treatment with galantamine (an AChE
inhibitor enhancing cholinergic signaling and also acting as
a positive allosteric modulator of a7 nAChR) (Albuquer-
que et al. 2001) significantly reduces body weight, food
intake, abdominal adiposity, plasma cytokine and adipo-
kine levels, and significantly improves blood glucose,
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insulin resistance and hepatic steatosis (Satapathy et al.
2011). These results suggest that galantamine has both a
central and a peripheral anti-inflammatory effect (Satapa-
thy et al. 2011). In conclusion, various rodent models of
obesity can benefit from activation of the nicotinic cho-
linergic signaling pathway (Table 1).
nAChR Subunits Involved and Genetic Models
Quantification of nAChR subunits in adipose tissue or
adipose cells from rodents and humans (summarized in
Table 2) as well as metabolic phenotyping of animal
models harboring a deficiency in nAChR subunits also
contribute to deeper understanding of the role of the nic-
otinic cholinergic pathway in adipose tissue development
and function. Gene expression of a1–7, a9, a10, b1–4, d
and e nAChR subunits can be detected in rat adipocytes, in
line with immunocytochemical labeling of a7 and b2
subunits (Liu et al. 2004). Functional binding of labeled
nicotine directly on adipocytes corroborate functionality of
these adipose nAChRs (Liu et al. 2004). In mice, the
expression pattern of nAChR subunits in WAT
(a2 [a5 [ b2 [a4) diverges from that of BAT
(a2 [b2 [ b4 [a5) (Gochberg-Sarver et al. 2012) sug-
gesting depot-specific functional roles. In link with these
basic observations, single nucleotide polymorphism (SNP)
in the a2 nAChR subunit appears as a risk factor for
overweight/obesity in a human cohort (Kim 2008). Genetic
deletion of AChE (as well as administration of AChE
pharmacological inhibitors) induces hypothermia associ-
ated with reduced nicotinic receptor currents in isolated
sympathetic ganglia neurons mediating the activation of
BAT (Sun et al. 2007). Chronic nicotine treatment
decreases gene expression of TNF-a, adiponectin and
monocyte chemoattractant protein-1 (MCP-1) in WAT and
those of TNF-a and adiponectin in BAT (Gochberg-Sarver
et al. 2012). b2 nAChR subunit deficiency (b2 nAChR-/-
mice) affects gene expression of cyclooxygenase 2 and
nerve growth factor b in WAT and those of leptin, cyclo-
oxygenase 2, adiponectin and haptoglobin in BAT
suggesting a role for this subunit in regulation of gene
transcription in adipose tissue (Gochberg-Sarver et al.
2012). The cholinergic anti-inflammatory pathway also
seems to play an important role in obesity-induced
inflammation of adipose tissue. In fact, metabolic pheno-
type of a7 nAChR-/- mice shows that their macrophages
present elevated proinflammatory cytokine production in
response to FFAs (Wang et al. 2011). Nicotine significantly
suppresses FFA- and TNF-a-induced cytokine production
in wild-type but not in a7 nAChR-/- macrophages, sug-
gesting that a7 nAChR mediates the anti-inflammatory
effect of nicotine (Wang et al. 2011). Inactivation of the
cholinergic anti-inflammatory pathway in the a7
nAChR-/- mouse model results in increased adipose tissue
infiltration of classically activated M1 macrophages and
inflammation leading to impaired insulin sensitivity inde-
pendent of any change in body weight (Wang et al. 2011).
These experimental observations in rodents are strikingly
highlighted by the recent investigations on a7 nAChR
subunits in human WAT. a7 nAChR expression appears
lowered in the subcutaneous adipose tissue of obese
humans compared with that of control subjects (Cancello
et al. 2012). In isolated mature adipocytes from highly
obese subjects, a7 nAChR expression and protein content
are 75 % lower compared with control subjects, whereas
weight loss induces an increase in a7 nAChR expression
(Cancello et al. 2012).
Cell Culture
Some molecular mechanisms involved in nicotinic cho-
linergic signaling in fat cells are more thoroughly
elucidated through in vitro experiments using adipocyte
cell lines or primary cultures. Exposure of 3T3L1 adipo-
cytes to nicotine increases lipolysis and inhibits fatty acid
synthase activity, phosphorylating both AMPK and acetyl-
CoA carboxylase (An et al. 2007). These effects appear to
be mediated through induction of reactive oxygen species
(An et al. 2007). In rat adipocyte primary culture, nicotine
induces a dose-responsive release of TNF-a, adiponectin
and FFA into the medium (Liu et al. 2004). In contrast,
TNF-a protein levels decrease in adipocytes, suggesting
that nicotine regulates time dependently the production and
secretion of adipokines (Liu et al. 2004). In mice adipocyte
primary cultures, application of nicotine after silencing the
b2 nAChR subunit significantly elevates the expression
level of cyclooxygenase-2 gene, corroborating a molecular
link between the b2 nAChR subunit and the expression
levels of specific adipokines also affected by nicotine
(Gochberg-Sarver et al. 2012). In vitro stimulation of
human adipocytes with the specific a7 nAChR agonist
PNU282987 induces a significant anti-inflammatory effect,
decreasing the pro-inflammatory up-regulation of inter-
leukin (IL)-6, MCP-1 and TNF-a genes induced by
lipopolysaccharide (Cancello et al. 2012). Likewise, a
genistein treatment inducing an increase in a7 nAChR
protein content results in a significantly decreased expres-
sion of IL-6 and MCP-1 genes in adipocyte culture
(Cancello et al. 2012).
Early Deleterious Programming Action
The programming phenomenon [also known as the Bar-
ker’s Hypothesis or Developmental Origins of Health and
Disease (DOHaD) theory] is a biological process under-
lying developmental plasticity. This concept of ‘‘fetal
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origin of adult diseases’’ suggests that a mismatch between
fetal expectation of the postnatal environment and actual
postnatal environment could contribute to later adult dis-
ease risk (Gluckman and Hanson 2004). For example,
maternal inadequate nutrition, which limits fetal growth
leading to low birth weight, predisposes to obesity in
adulthood, especially when postnatal nutrition is highly
caloric (Hales and Barker 1992). Voluntary or passive
exposure to chemical pollutants also contribute to inade-
quate intrauterine environment, and despite medical advice
more than 10 % women continue smoking during preg-
nancy (for review see Somm et al. 2009). In contrast to the
direct lipolytic and anti-inflammatory action of nicotinic
cholinergic signaling previously discussed, fetal nicotinic
exposure seems to present an opposite effect by program-
ming excessive adipose tissue development later in life.
Epidemiological studies have correlated maternal smoking
during pregnancy with increased risk of obesity in children
at different ages (Al Mamun et al. 2006; Koupil and Toi-
vanen 2008; Mizutani et al. 2007; Ong et al. 2002; Power
and Jefferis 2002; Sowan and Stember 2000; Toschke et al.
2002a, b). Animal studies show that nicotine exposure
mimics the effect of maternal tobacco consumption on
obesity occurrence in the offspring (for review see Somm
et al. 2009). Initial observations showing elevation in body
fat proportion by one-third just before birth in rat fetuses
prenatally exposed to nicotine (Williams and Kanagasabai
1984) are corroborated by more recent studies. Epididymal,
mesenteric and perirenal fat pad weights are increased in
adulthood in Wistar rats perinatally exposed to nicotine
(Gao et al. 2005). Epididymal fat pad weight is also heavier
at weaning in Sprague–Dawley rats exposed to nicotine
during their uterine life, mainly due to enhanced differen-
tiation of their adipocytes (Somm et al. 2008). Prenatal
nicotine exposure also exacerbates post-weaning weight
gain and fat deposition caused by high-fat diet consump-
tion (Somm et al. 2008). Maternal nicotine exposure
restricted to the lactating period also leads to early and late
metabolic defects. Higher levels of HDL-C, leptin, corti-
costerone and adrenal catecholamine content are observed
at PND15, (Oliveira et al. 2010) and overweight (with
increased fat mass and hypertrophy of adipocyte), hyper-
leptinemia (with impaired hypothalamic leptin signaling),
hyperinsulinemia and hypothyroidism are reported in adult
rat offspring exposed to nicotine through maternal milk (de
Oliveira et al. 2010). Different mechanisms could explain
the enhanced adipose storage due to early nicotine expo-
sure during the early stage of development such as (1)
increased release and transport of fatty acids from maternal
adipose tissue to the fetal circulation (Williams and Ka-
nagasabai 1984), (2) a nicotine-mediated stimulatory effect
on PPAR-c gene expression in the adipocyte (Somm et al.
2008), as previously observed in monocytes (AmorusoT
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et al. 2007); (3) decreased physical activity [linked to
alterations in motor behavior related to disruptions in the
mesoaccumbens dopaminergic pathway (Oliff and Gal-
lardo 1999)]; and (4) decreased cold-induced
thermogenesis [in accordance with alterations in adrenergic
responsiveness of sympathetic target tissues (Navarro et al.
1990) and blunted sympathetic responsiveness leading to
hypoactivity of the noradrenergic system (Levin 2005)].
Nicotinic Cholinergic Signaling in Pancreatic Islet
Biology and Therapeutic Perspectives in the Treatment
of Diabetes
Pancreatic islets (also named Langerhans islets) are clus-
ters of endocrine cells which represent approximately
1–2 % of the mass of the whole pancreatic tissue. These
endocrine structures play a central role in metabolism
through direct secretion into the blood flow of key hor-
mones involved in the regulation of nutrient uptake or
transformation. b Cells (producing insulin, c-peptide and
amylin) and a cells (producing glucagon) are the major cell
types present in pancreatic islets; other cell types include d
cells (producing somatostatin), PP cells (producing pan-
creatic polypeptide) and e cells (producing ghrelin). In
addition to nutritional, hormonal and paracrine regulatory
mechanisms, the secretory activity of pancreatic islets is
under tight control of the autonomic nervous system
involving cholinergic signaling, as demonstrated by the
tenfold higher activity of CHAT and AChE in the islets
compared to the surrounding exocrine tissue (Godfrey and
Matschinsky 1975). At the sympathetic level, the pregan-
glionic fibers release ACh that acts on nicotinic receptors
on intraganglionic neurons, whereas the postganglionic
fibers release several neurotransmitters including norepi-
nephrine (Ahren 2000; Cerf 2011; Gilon and Henquin
2001; Woods and Porte 1974). Sympathetic islet innerva-
tion lowers insulin and stimulates glucagon release to
maintain or increase glycemia in stress conditions such as
neuroglycopenia or physical exercise (Ahren 2000; Cerf
2011; Gilon and Henquin 2001; Woods and Porte 1974). At
the parasympathetic level, the preganglionic fibers reach
Table 2 Detection of nAChR subunits in adipose or pancreatic islet cells and tissues
Tissue/cell line Specie nAChR subunits Method of
detection
Remarks References
Adipose tissue
Epididymal WAT Mice a2 [a5 [b2 [ a4 qPCR In b2 nAChR-/- mice, the expression levels of Cox2 and
Ngfb genes are significantly altered in WAT
Gochberg-Sarver
et al. (2012)
Interscapular BAT Mice a2 [b2 [b4 [ a5 qPCR In b2 nAChR-/- mice, the expression levels of Leptin, Cox2,
AdipoQ and haptoglobin are significantly altered in BAT
Gochberg-Sarver
et al. (2012)
Subcutaneous WAT Human a7 qPCR Gene expression of a7 nAChR is reduced in obese subjects Cancello et al.
(2012)
Isolated mature
adipocyte
Human a7 qPCR/WB a7 nAChR expression is higher in mature adipocytes than in
whole adipose tissue. a7 nAChR in adipocytes of obese
subjects is significantly lowered (mRNA and protein). In
obese subjects, weight loss increases a7 nAChR expression
Cancello et al.
(2012)
Epididymal WAT Mice a7 qPCR The expression of a7 nAChR tends to be higher in adipose
macrophages than in isolated adipocytes.
Butyrylcholinesterase is the major cholinesterase in adipose
tissue (up-regulated with chronic nicotine treatment, down-
regulated in DIO and in db/db mice)
Wang et al.
(2011)
In vitro
differentiated
adipocyte
Rat a1–7, 9, 10, b1–4,
d, e
PCR/IHC Functionality of nAChRs expression is also substantiated by a
dose-dependent binding of labeled nicotine
Liu et al. (2004)
Pancreatic islet cell
Islet (b cell) Rat a7 IHC a7 nAChR subunit is expressed in the central part of the islets
and co-localizes with insulin, ChAT, VAChT while AChE
expression is stronger in the surrounding, exocrine tissue
and in the mantle region of the islet
Delbro (2012)
INS-1 (b cell line) Rat a2, a3, a4, a5, a7,
b2
PCR Binding of a-bungarotoxin and cytisine indicates functionality
of these subunits in INS-1 cells and rat islets
Yoshikawa et al.
(2005)
TC6 insulinoma
cells (b cell line)
Mice a3, a4, b2, b4 PCR a5 nAChR subunit mRNA is also detected, whereas mRNAs
for a2, a6, and a7 nAChR subunits are not detected.
Nicotinic agonists (epibatidine [ nicotine & cytisine,
A-83850, and DMPP) also elicit increases in intracellular
calcium. Binding results with [3H]epibatidine demonstrate
high levels of nicotinic receptors with high affinity
Ohtani et al.
(2006)
AdipoQ adiponectin, Cox2 cyclooxygenase-2, DMPP dimethylphenylpiperazinium
94 Arch. Immunol. Ther. Exp. (2014) 62:87–101
123
intrapancreatic ganglia dispersed in the exocrine tissue and
unmyelinated postganglionic fibers leave the ganglia
toward the islets (Ahren 2000; Cerf 2011; Gilon and
Henquin 2001; Woods and Porte 1974). Preganglionic
vagal fibers release ACh that binds to nicotinic receptors on
intraganglionic neurons and postganglionic vagal fibers
release several neurotransmitters including ACh. Para-
sympathetic islet innervation stimulates insulin, glucagon
and PP release (Ahren 2000; Cerf 2011; Gilon and Henquin
2001; Woods and Porte 1974).
The muscarinic receptor is classically described as the
terminal effector of cholinergic signaling in pancreatic b
cells (Gilon and Henquin 2001; Lundquist 1982; Ruiz de
Azua et al. 2012), and the function of nicotinic cholinergic
receptors in the context of pancreatic islets has long been
limited to their role in ganglionic autonomic neurotrans-
mission. Nicotinic cholinergic signaling stimulates vagal
transmission in ganglionic neurons, and nAChR agonists,
including nicotine, mimic this vagal signaling (Ahren et al.
1986; Ahren and Taborsky 1986; Kirchgessner and Liu
1998; Nishi et al. 1987; Sha et al. 1997; Stagner and
Samols 1986).
More recent direct detection of nAChRs in immune and
islet cells leads to revise the potential role of the nicotinic
cholinergic pathway in endocrine pancreas physiology and
diseases. Species differences in morphological organiza-
tion of pancreatic islets need to be considered in this
context. In contrast to rodent islets, harboring a central core
of b cells surrounded by peripheral a cells in the mantle
position, the cytoarchitecture of human islets does not
show such distinct anatomical subdivisions with a, b and d
cells scattered throughout the islet, complicating a precise
order of paracrine interactions (Cabrera et al. 2006). The
innervation pattern of islets also seems to be different
between rodents and humans. Visualization of axons in
three dimensions and quantification of axonal densities and
contacts within pancreatic islets show that human endo-
crine cells are sparsely contacted by autonomic axons
(Rodriguez-Diaz et al. 2011a). Few parasympathetic cho-
linergic axons penetrate the human islet, and the invading
sympathetic fibers preferentially innervate smooth muscle
cells of blood vessels located within the islet, suggesting a
role in the control of local blood flow (Rodriguez-Diaz
et al. 2011a). Poor cholinergic innervation of human islets
appears to be substituted by the a cells which provide
paracrine cholinergic input to surrounding endocrine cells
(Rodriguez-Diaz et al. 2011b). ACh secretion by a cells
seems to sensitize the b cell response to increase in glucose
concentration (Rodriguez-Diaz et al. 2011b), making the
paracrine cholinergic signaling within islets a potential
therapeutic target in diabetes. In rodents, the expression of
ChAT, VAChT, CHT-1 and a7 nAChR is identified in the
core of islets (b cells), and expression of AChE is stronger
in the surrounding exocrine tissue and in the mantle region
of the islet (Delbro 2012), suggesting that rat b cells pro-
duce ACh which could in an autocrine/paracrine
mechanism participate in insulin secretion via a7 nAChR
receptors. Some previous functional experiments substan-
tiate this histologically based hypothesis and attribute a
primary role to nicotinic cholinergic signaling in pancreatic
islet secretion. In islets isolated from rats, exposure to the
muscarinic receptor blocker, atropine, suppresses insulin
release, whereas a-bungarotoxin (antagonist of the a7
nAChR) increases insulin and glucagon release (Ejiri et al.
1989, 1990), suggesting that not only muscarinic but also
nicotinic cholinergic receptors influence insulin release in
isolated islets. In rat and human islets, nicotine moderately
inhibits insulin release, both in the presence of basal and
elevated glucose levels (Yoshikawa et al. 2005). Specific
binding of labeled nicotine is demonstrated in rat islets as
well as in INS-1, a rat b cell line expressing a2, a3, a4, a5,
a7 and b2 nAChR subunits (Yoshikawa et al. 2005).
Cytisine (a partial agonist of a4/b2*nAChRs and a full
agonist of a3/b4*nAChRs) partially inhibits tolbutamide-
induced insulin release (by direct closure of K?-ATP
channels) in INS-1 cells (Yoshikawa et al. 2005). In con-
trast, specific binding of a-bungarotoxin slightly increases
insulin release in INS-1 cells (Yoshikawa et al. 2005). In
mice b-TC6 insulinoma cells harboring a3, a4, b2, b4
nAChR subunits, nicotine elicits membrane depolarization,
elevation of intracellular calcium and release of insulin
(Ohtani et al. 2006). In these b-TC6 insulinoma cells, the
maximal elevation of cytoplasmic [Ca2?] induced by car-
bamylcholine (a mixed muscarinic/nicotinic receptor
agonist) is greater than that of oxotremorine M (a selective
muscarinic agonist) or nicotine alone (Ohtani et al. 2009).
Nevertheless, carbamylcholine induces a smaller extent of
insulin secretion than oxotremorine M, suggesting a neg-
ative type of interaction between nicotinic and muscarinic
cholinergic receptors (Ohtani et al. 2009). Together, these
observations suggest the presence of a functional nicotinic
cholinergic system in isolated rodent and human pancreatic
islets, as well as in available endocrine b cell lines
(Table 2). In contrast to muscarinic cholinergic signaling,
nicotinic cholinergic signaling in islets seems rather to
dampen insulin secretion through presently unknown
mechanisms. Nevertheless, several studies have success-
fully investigated the therapeutic perspectives proposed by
nicotinic cholinergic pathways in the pathological context
of diabetes.
Type 1 Diabetes
Type 1 diabetes (T1D) is a juvenile disease due to immune
destruction of the insulin-producing pancreatic b cells
(Noorchashm et al. 1997). Experimentally, rodent models
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of the disease range from animals with spontaneously
developing autoimmune diabetes (NOD mice, BB rats) to
chemical ablation of the pancreatic beta cells (with strep-
tozotocin or alloxan) (King 2012).
In vitro, stimulation of the muscarinic receptor by car-
bachol protects islets from the apoptotic/necrotic action of
cytokines characteristic of T1D (Laychock et al. 2006).
Interestingly, nicotinic cholinergic signaling could also
present protective effects. In fact, nicotine administration
reduces hyperglycemia and preserves pancreatic insulin
content, reducing the incidence of T1D in both streptozo-
tocin-treated and NOD mice (Mabley et al. 2002).
Mechanistically, the elevated levels of pro-inflammatory
cytokines (IL-12, IL-1, TNF-a, and interferon c) are down-
regulated in pancreas of both diabetic models by nicotine
administration (Mabley et al. 2002). In contrast, nicotine
increases the pancreatic levels of anti-inflammatory cyto-
kines (IL-4 and IL-10), suggesting that nicotinic
cholinergic signaling reduces the incidence of T1D in
rodent models by shifting the profile of pancreatic cytokine
expression from helper T cells type1 to type2 (Mabley
et al. 2002).
Type 2 Diabetes
Type 2 diabetes (T2D also known as noninsulin-dependent
diabetes or adult-onset diabetes) is primarily due to
increased peripheral insulin resistance which challenges
the capacity of the b cells to produce a compensative
amount of insulin. The pathology is generally linked to
increased fat mass and animal models mimicking the dis-
ease involve for example genetic mutation in leptin gene
(ob/ob mice), in leptin receptor gene (db/db mice or Zucker
fatty rats) or diet-induced obesity (DIO) (King 2012).
Clinically, a genetic study involving multiple SNP
analysis reveals significant associations between variants in
the a5/a3/b4 nAChR gene cluster with both insulin resis-
tance and T2D (Yang et al. 2012). In control rats, nicotine
administration reduces insulinemia and globally improves
insulin sensitivity (Xu et al. 2012). In Zucker fatty rats
chronically exposed to nicotine, both basal and post-glu-
cose tolerance test glycaemia are reduced (Liu et al. 2001).
In this model, nicotine administration reduces pancreatic
islet size (without change in a/b cell mass proportion) (Liu
et al. 2001). Further investigations reveal that chronic
nicotine treatment in Zucker fatty rats does not impact
body weight and food intake, but improves insulin sensi-
tivity in link with a liver-specific attenuation of
glycogenogenesis and gluconeogenesis (Liu et al. 2003). In
db/db and in DIO mice, nicotine administration improves
glucose homeostasis and insulin sensitivity also indepen-
dently of any change in body weight (Wang et al. 2011),
but in connection with an a7 nAChR role on glucose
metabolism. a7 nAChR2/2 mice are gluco-intolerant and
resistant to insulin without change in body weight or
insulin secretion (Wang et al. 2011). Likewise, nicotine-
induced insulin-sensitizing action is abrogated in a7
nAChR2/2 mice (Xu et al. 2012). a7 nAChR deficiency
seems to elevate adipose tissue infiltration by classically
activated macrophages and leads to an inflammatory-prone
status which induces insulin resistance. In contrast, phar-
macological administration of the a7 nAChR agonist TC-
7020 to db/db obese mice reduces their elevated glucose
levels and lowers their elevated plasma levels of triglyc-
erides and TNF-a (Marrero et al. 2010). These benefits are
abolished by both the a7-selective antagonist methyllyca-
conitine and a Janus kinase 2 inhibitor, confirming the
involvement of a7 nAChRs and the downstream JAK2/
STAT3 signaling pathway (Marrero et al. 2010). Chronic
treatment with the selective a7 nAChR agonist PNU-
282987 significantly enhances insulin sensitivity in normal
mice as well as in insulin-resistant AMP-activated kinase-
a22/2 mice, also in link with enhanced phosphorylation of
STAT3 (Xu et al. 2012).
Together, these preclinical observations in animals
suggest that peripheral nicotinic cholinergic signaling
could represent a potential therapeutic target for the dif-
ferent forms of diabetes (Table 1).
Early Deleterious Programming Action
In contrast to the insulin-sensitizing and anti-inflammatory
action of nicotinic cholinergic signaling previously dis-
cussed, fetal nicotinic oversignaling seems to present a
deleterious action in programming altered glucose
homeostasis later in life. Recent data suggest that insulin
resistance and T2D could be ‘‘programmed’’ during intra-
uterine life by diverse insults to the growing fetus (Berends
and Ozanne 2012), including exposure to endocrine dis-
ruptors (Alonso-Magdalena et al. 2011). In this context,
developing fetuses can be widely exposed to tobacco and
nicotine (Althabe et al. 2008; Martin et al. 2005; Nabet
et al. 2005) and epidemiological studies have demonstrated
an increased prevalence of diabetes in children born to
smoking women (Montgomery and Ekbom 2002). This
clinical observation is corroborated by several animal
studies investigating the impact of early life exposure to
nicotine on endocrine pancreas development and later
control of glucose homeostasis. a2–a4, a6, a7 and b2–b4
nAChR subunits can be detected early in the developing rat
pancreas (Bruin et al. 2008b), suggesting a primary dele-
terious effect of prenatal nicotine exposure on the
development of this organ. Rat offspring exposed to nico-
tine during fetal and neonatal life present increased b cell
apoptosis at birth (Holloway et al. 2005) and reduced b cell
mass in adulthood, indicating a permanent b cell loss
96 Arch. Immunol. Ther. Exp. (2014) 62:87–101
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(Bruin et al. 2007). Islet size, number and transcriptional
activity are reduced on postnatal day 7 due to prenatal
nicotine exposure in rats (Somm et al. 2008). Underlying
molecular mechanisms involved in nicotine-induced b cell
apoptosis during development include (1) the death
receptor pathway [with elevated Fas and soluble FasL
levels (Bruin et al. 2008a)], (2) the mitochondrial pathway
[with increases in the ratio of Bcl2/Bax, Bax translocation
to the mitochondria and cytochrome c release to the cytosol
(Bruin et al. 2008a)], (3) oxidative stress [with increased
pancreatic glutathione peroxidase and manganese super-
oxide dismutase protein expression consecutive to
induction of reactive oxygen species production (Bruin
et al. 2008b)]. These early morphological and molecular
alterations lead to later defect in control of glucose
homeostasis. Animal models exposed early to nicotine
show glucose intolerance (Holloway et al. 2005; Somm
et al. 2008) associated with insulin resistance (Somm et al.
2008). Impairment in glucose homeostasis caused by
perinatal nicotine exposure also seems to be transgenera-
tional (Holloway et al. 2007), suggesting nicotine-induced
epigenetic modifications persisting throughout generations.
Conclusion
nAChRs represent a large and complex family of ligand-
gated ion channels that are widely expressed in the synapse
of the central and peripheral nervous system and the neu-
romuscular junction. More recently, new functions in
intracellular signaling and detection in the peripheral non-
neuronal cell have renewed the interest for this class of
receptors in various fields of investigation.
In the present review, we focus our attention on the role
of nAChRs in adipose tissues and pancreatic islet biology,
as well as on the potential therapeutic perspectives for
nicotinic cholinergic signaling through these nAChRs in
metabolic diseases such as obesity and diabetes. In fact,
various nAChR subunits are expressed in pancreatic islet
cells, adipocytes and, also importantly, in immune cells
interacting with them. Independently of its well-known
central anorexigenic action, experimental exposure to nic-
otine or other nAChR agonists activates lipolytic activity in
WAT and thermogenic activity in BAT through both ner-
vous and non-nervous mechanisms. Moreover, moderate
doses of nicotine seem to be effective in reducing the
inflammation process linked to obesity. These actions
allow dampening metabolic defects in various rodent
models of genetic and nutritional obesity. Anti-inflamma-
tory and insulin-sensitizing properties of the nicotinic
cholinergic signaling pathway also show therapeutic ben-
efit for the treatment of T1D and T2D in preclinical studies.
Metabolic phenotyping of mice deficient in some nAChR
subunits (in particular, a7 nAChR) confirms this rationale
considering nicotinic cholinergic signaling as a treatment
for metabolic syndrome. Keeping in view that nicotine
stimulates non-specifically all types of nAChRs, leading to
toxic effects at high doses, and that the a7 nAChR seems to
be the subtype most involved in inflammation and insulin
sensitivity improvement, development and testing of new
specific a7 nAChR agonists represent a rather promising
new pharmacotherapeutic approach.
In contrast to potential therapeutic use in metabolic dis-
eases, an overstimulation of this signaling pathway during
the early stage of development (typically through nicotine
exposure during fetal life) presents deleterious consequences
in the ontogeny and functionality of adipose tissue and the
endocrine pancreas which persist throughout life.
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